This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Schools across the country are determined to keep class in session, despite the rapidly-spreading Omicron variant. While many parents prefer in-person learning, they also worry whether the current public health guidelines will be enough to protect their kids. Erin Richards, national education reporter for USA Today, joined Cheddar to discuss how are schools are preparing for the surge to avoid another round of remote learning.
With the annual CES convention underway amid COVID, HP unveiled rolled out a number of new products virtually this year, including new gaming PCs and 4K display monitors. But as industries look toward a greener future, HP is working with the climate crisis in mind. James McCall, chief sustainability officer at HP, joined Cheddar's Kristen Scholer to discuss the company's climate goals, which includes reducing its carbon footprint to net-zero by 2040. He admitted that reaching the ambitious goal will be difficult because much of the company's emissions totals come from third parties. "A large part of our footprint is outside of HP's direct control. A lot of it comes either from our incoming supply chain, the materials, our manufacturing process, or about 30 to 40 percent of it comes from our consumer-use base," McCall told Cheddar.
Pfizer and BioNTech are working to develop an mRNA-based shingles vaccine following the success of the COVID-19 shot. This latest collaboration will mark the third time the pharmaceutical companies have worked together on a vaccine.
The potential collapse of the Thwaites glacier in Antarctica has been deemed a potential "doomsday event" — researchers and scientists say its melting and collapse could raise global sea levels by at least two feet, enough to destroy coastal communities around the world. One team of scientists is traveling to the Thwaites glacier to drill below in order to gauge current ocean temperatures and attempt to model possible outcomes. David Holland, professor at NYU and Principal Investigator for the International Thwaites Glacier Collaboration, joins Cheddar Climate to discuss the glacier's potential collapse, his team's research plan, and more.
As winter break wraps up and COVID-19 cases hit record levels, the majority of school districts are returning to in-person classes. While some public schools in large cities have shifted to remote learning for the beginning of the year, the schools that are reopening campuses are determined to avoid the academic, social, and logistical challenges that come with a virtual classroom. Cheddar News is joined by Keith Powers, NYC Council Member, to discuss.
With a rising number of COVID-19 cases due to the omicron variant, the FDA is making big moves. First, Pfizer's COVID-19 booster has been authorized for those ages 12 to 15. The agency also reduced the amount of time to wait between receiving a second vaccine dose and booster from six months to five. Finally, a third primary series dose of Pfizer's shot is approved for immunocompromised children five to 11 years old. Professor Peter Pitts joins Cheddar News to discuss.
California's new composting law will affect what residents do in their kitchens. As of this week, Californians will have to recycle excess food in an effort to reduce emissions caused by food waste. Cities and counties will turn recycled food into compost or use it as a renewable energy source. California's new law is the largest mandatory residential food waste recycling program in the country. Rachel Wagoner, Director of the California Department of Resources, Recycling and Recovery called the law 'the biggest change to trash' since recycling started in the 1980s. She joined Cheddar Climate to discuss.
Deborah Brosnan, President of Deborah Brosnan & Associates, joins Cheddar Climate, where she explains why global warming brought about 'a year of reckoning' in 2021 and why previously unprecedented weather events could become the norm going forward.
On this episode of Cheddar Reveals, Dr. Anita Gupta, Adjunct assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine, shares her forecast for the healthcare industry in 2022; Waseem Asghar, Ph.D., Associate Professor, Department of Computer & Electrical Engineering and Computer Science, Florida Atlantic University, breaks down the latest progress, trends, and innovations in wearable health tech; Cheddar gets a look at Curiosity Stream's 'Hacking our Biome.'
Dr. Anita Gupta, Adjunct assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine, joins Cheddar Reveals to share her forecast for the healthcare industry in 2022.
